Leeward Investments LLC MA Cuts Position in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Leeward Investments LLC MA lowered its stake in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 4.5% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 359,898 shares of the company's stock after selling 16,782 shares during the period. Prestige Consumer Healthcare accounts for about 1.6% of Leeward Investments LLC MA's investment portfolio, making the stock its 6th largest position. Leeward Investments LLC MA owned about 0.73% of Prestige Consumer Healthcare worth $30,940,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. Opal Wealth Advisors LLC bought a new stake in shares of Prestige Consumer Healthcare during the first quarter valued at approximately $38,000. CIBC Private Wealth Group LLC raised its position in shares of Prestige Consumer Healthcare by 48.9% during the fourth quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company's stock valued at $34,000 after buying an additional 152 shares during the last quarter. Headlands Technologies LLC bought a new stake in shares of Prestige Consumer Healthcare during the fourth quarter valued at approximately $40,000. McIlrath & Eck LLC increased its holdings in shares of Prestige Consumer Healthcare by 19.1% in the fourth quarter. McIlrath & Eck LLC now owns 959 shares of the company's stock worth $75,000 after purchasing an additional 154 shares during the last quarter. Finally, Johnson Financial Group Inc. bought a new stake in shares of Prestige Consumer Healthcare in the fourth quarter worth about $93,000. Institutional investors own 99.95% of the company's stock.

Prestige Consumer Healthcare Trading Down 0.2%

PBH traded down $0.20 on Friday, hitting $79.98. The company had a trading volume of 243,045 shares, compared to its average volume of 306,011. The company has a market cap of $3.95 billion, a PE ratio of 18.64, a PEG ratio of 2.41 and a beta of 0.43. Prestige Consumer Healthcare Inc. has a 12-month low of $64.94 and a 12-month high of $90.04. The company has a quick ratio of 2.82, a current ratio of 4.20 and a debt-to-equity ratio of 0.55. The business's fifty day simple moving average is $84.18 and its 200 day simple moving average is $82.38.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported $1.32 EPS for the quarter, topping the consensus estimate of $1.30 by $0.02. The company had revenue of $296.52 million during the quarter, compared to analyst estimates of $289.36 million. Prestige Consumer Healthcare had a return on equity of 12.87% and a net margin of 18.86%. The firm's revenue was up 7.0% on a year-over-year basis. During the same quarter last year, the business posted $1.02 earnings per share. Equities research analysts expect that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Wall Street Zen raised Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a research note on Saturday, May 17th. Royal Bank Of Canada raised Prestige Consumer Healthcare to a "hold" rating in a report on Thursday, May 8th. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $93.33.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.